Laboratory markers of metabolic syndrome in clinical practice

Česká verzia

Authors: V. Soška ^1,2
Authors place of work: Oddělení klinické biochemie FN u sv. Anny Brno, přednosta doc. MUDr. Vladimír Soška, CSc. ¹; II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc. ²
Published in the journal: Vnitř Lék 2009; 55(7-8): 666-669
Category: 134th Internal Medicine Day - 23rd Vanysek's Day Brno 2009 - Vanysek's Lecture

Summary

The incidence of metabolic syndrome is evidenced by the presence of three out of five criteria:
larger waistline, elevated blood pressure, raised triglyceride levels, reduced HDL-cholesterol and raised fasting glycaemia (or diabetes mellitus). Laboratory picture of metabolic syndrome also includes presence of small LDL₃ particles and increased concentration of apolipoprotein B. Determination of glycaemia and triglycerides and HDL-cholesterol levels is fundamental for the diagnosis of metabolic syndrome. The risk of the so-called „pre-analytical” error has to be minimized in order for the results of these investigations to be sufficiently reliable, i.e. the recommendations related to the preparation of the patient, blood sampling itself and the transportation of the sample to a laboratory has to be adhered to. If the laboratory results fall into the borderline (critical) values, it is appropriate to repeat blood sampling.

Key words:
metabolic syndrome – glycaemia – triglycerides – HDL-cholesterol – apolipoprotein B – pre-analytical error

Zdroje

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

2. Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten country panel. J Intern Med 2006; 259: 247–258.

3. Horák P. Metodická úskalí stanovení LDL cholesterolu. Labor Aktuell (CS) 2001; 2: 8–12.

4. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181–197.

5. Cífková R, Býma S, Češka R et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitř Lék 2005; 51: 1021–1036.

6. Sacks FM. Expert Group on HDL cholesterol. The role of high‑density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 2002: 90: 139–142.

7. Assmann G, Schulte H. Relation of high‑density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster Study. Am J Cardiol 1992; 70: 733–737.

8. Gallin JI, Kaye D, O’Leary WM. Serum lipids in infection. N Engl J Med 1969; 281: 1081–1086.

9. Crouse JR, Grundy SM. Effects of alcohol on plasma lipoproteins and cholesterol and triglyceride metabolism in man. J Lipid Res 1984; 25: 486–496.

10. Baraona E, Lieber CS. Alcohol. In: Betteridge DJ, Illingworth DR (eds). Lipoproteins in health and disease. London: Arnold 1999: 1011–1036.

11. Miller M, Bachorik PS, Cloey TA. Normal variation of plasma lipoproteins: postural effects on plasma concentration of lipids, lipoproteins and apolipoproteins. Clin Chem 1992; 38: 569–574.

12. Page IH, Moinuddin M. The effect of venous occlusion on serum cholesterol and total protein concentration – a warning. Circulation 1962; 25: 651–652.

13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.